John Raymond Murphy insider trades
Open-market stock purchases and sales by John Raymond Murphy, Director at Cadrenal Therapeutics, Inc, from SEC Form 4 filings since Mar 23, 2010.
Track record: 50% of 8 scored buys are up 5% or more since purchase, averaging +13%.
Get free alerts when John Raymond Murphy files a new trade →